Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DDBSD

Financiado

Cerrado

Diagnostic Test For The Differential Diagnosis of Bipolar Disorder and Major Dep...

Diagnostic Test For The Differential Diagnosis of Bipolar Disorder and Major Depressive Disorder Neuropsychiatric disorders contribute 13% to the global burden of disease and cost the European economy an estimated 789bn EUR a year. PsyOmics is a Cambridge-based biotechnology start-up focused on reducing this burden by providi... ver más

30/11/2016

INTBAU

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

INTBAU No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-11-30

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INTBAU

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PReDicT Predicting Response to Depression Treatment 71K€ Cerrado

ENBREC European Network of Bipolar Research Expert Centres 877K€ Cerrado

ClinGen-PsychTx Identifying Clinical Demographic and Genomic Risk Factors... 186K€ Cerrado

POSTPARTUM BID Improving prediction of the triggering of bipolar disorder e... 282K€ Cerrado

AI-DIAGNOSE Machine learning for diagnosis of bipolar disorder detectio... 181K€ Cerrado

BBFGEN Genetic analysis of rare and common variation in a large Bra... 183K€ Cerrado

Duración del proyecto: 9 meses Fecha Inicio: 2016-02-26
Fecha Fin: 2016-11-30

Líder del proyecto

INTBAU No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Neuropsychiatric disorders contribute 13% to the global burden of disease and cost the European economy an estimated 789bn EUR a year. PsyOmics is a Cambridge-based biotechnology start-up focused on reducing this burden by providing scientifically-validated solutions that improve the prevention, diagnosis and treatment of psychiatric disorders. This project relates to the first clinical diagnostic that we intend to bring to market, a test to improve the diagnosis of bipolar disorder and major depressive disorder. It is estimated that 33.4m people within the WHO European region suffer from major depression each year, and around 7m suffer from bipolar disorder. The separation of these two groups for appropriate treatment is very challenging because patients with an underlying bipolar disorder typically present with depressive symptoms that are indistinguishable from those of MDD. The result is that around 40% of all patients with an underlying bipolar disorder are initially misdiagnosed with depression and prescribed antidepressants, rather than mood stabiliser treatments. On average it takes over 7.5 years for the correct diagnosis to be reached. There is no evidence to suggest that antidepressant monotherapies are effective in treating bipolar disorder and furthermore they are known to lead to an increased risk of anti-depressant induced mania, rapid cycling and suicide attempts among these patients, all of which lead to an increased rate of hospitalisation and healthcare costs. Our clinical diagnostic will reduce this level of misdiagnosis by enabling GPs and Psychiatrists to efficiently identify those that have an underlying bipolar disorder amongst those that present with depressive symptoms.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores